Georgia's Online Cancer Information Center

Cancer-Related Syndrome Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Cancer-Related Syndrome
Cancer Type = Cancer-Related Syndrome
There are currently 17 active Cancer-Related Syndrome clinical trials in Georgia.
1.
Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients with Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
Cancer Type
Cancer-Related Syndrome
NCT ID
NCT03321643
Protocol IDs
10126
10126
NCI-2017-01957
PHI-96
Treatment Sites (2)
2.
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)
Cancer Type
Cancer-Related Syndrome, Hodgkin Lymphoma, Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma
NCT ID
NCT03904134
Protocol IDs
BMT CTN 1702
NCI-2019-03477
N00014-18-1-2888
5U24HL138660-02
3.
Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Cancer Type
Cancer-Related Syndrome, Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02912559
Protocol IDs
A021502
A021502
NCI-2016-01417
A021502
4.
NCORP Trial
Connect® Myeloid Disease Registry
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT01688011
Protocol IDs
Connect® MDS/AML Registry
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
5.
Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03263091
Protocol IDs
FGCL-4592-082
NCI-2017-02071
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02152956
Protocol IDs
CP-MGD006-01
NCI-2014-01526
Treatment Sites (1)
7.
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04313881
Protocol IDs
5F9009
NCI-2020-03406
2020-004287-26
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT04762875
Protocol IDs
145-ADS-202
NCI-2021-03246
9.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT03150914
Protocol IDs
RLDC5713
NCI-2019-08422
U01HL131755-01
Treatment Sites (1)
10.
N-803 in Preventing Relapse in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome That Have Undergone a Donor Stem Cell Transplant
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02989844
Protocol IDs
2016LS058
NCI-2017-01046
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT02343224
Protocol IDs
IRB00074563
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
12.
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02521493
Protocol IDs
AAML1531
NCI-2015-00324
Treatment Sites (1)
13.
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT03013998
Protocol IDs
BAML-16-001
NCI-2017-00278
Treatment Sites (1)
14.
Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and/or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT04201457
Protocol IDs
PBTC-055
PBTC-055
NCI-2019-06216
15.
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Plasma cell neoplasm
NCT ID
NCT03805789
Protocol IDs
CSL964_2001
NCI-2019-03310
2018-000329-29
Treatment Sites (1)
16.
NCORP Trial
Tissue Collection and Natural History Study of Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasms
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCT ID
NCT02775383
Protocol IDs
NHLBI-MDS
NCI-2016-00281
Treatment Sites (15)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
17.
Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Cancer Type
Cancer-Related Syndrome, Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03190915
Protocol IDs
ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.